Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Stock Information for CloudMD Software & Services Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CloudMD Software & Services Inc

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement
Relmada Issues Mid-Year CEO Letter to Shareholders
Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01
DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.